TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01542788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) was administered as a tablet orally according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match SOF
Description: Placebo to match SOF was administered orally once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match RBV
Description: Placebo to match RBV was administered orally twice daily.
Study: NCT01657357

Intervention type: OTHER
Intervention: Routine followup
Description: questionnaires
Study: NCT06443814

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: This was a didactic classroom-based control which educates the patient on adapting a healthier lifestyle through proper diet, exercise, and moderating substance usage according to current AHA guidelines. This intervention does not include a stress management component.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation
Description: TM was taught in a standardized and validated format as a simple, natural mental technique practiced for 20 minutes twice a day (morning and evening) to give rest and relaxation to mind and body. TM was taught by a certified instructor and a 7-step process taking place over 4 consecutive days after which the meditator can practice at home twice a day.
Study: NCT04526665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elafibranor 80mg
Description: Elafibranor 80mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elafibranor 80mg
Description: Elafibranor 80mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily
Study: NCT03601897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebastinib
Description: Administered orally
Study: NCT03000309

Intervention type: DRUG
Group type: OTHER
Intervention: Apremilast
Study: NCT03601897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebastinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebastinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebastinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebastinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebastinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebastinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebastinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebastinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebastinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebastinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel administered by IV infusion at 80 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel administered by IV infusion at 80 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel administered by IV infusion at 80 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel administered by IV infusion at 80 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel administered by IV infusion at 80 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel administered by IV infusion at 80 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel administered by IV infusion at 80 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel administered by IV infusion at 80 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel administered by IV infusion at 80 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel administered by IV infusion at 80 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel administered by IV infusion at 80 mg/m\^2
Study: NCT01088906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed/Cisplatin
Description: Pemetrexed 500 mg/m2 IV followed by cisplatin 75 mg/m2 IV every 21 days. A cycle is 21 day.
Study: NCT01235949

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK1024850A (SynflorixTM)
Description: Intramuscular injection, 4 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK1024850A (SynflorixTM)
Description: Intramuscular injection, 4 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK1024850A (SynflorixTM)
Description: Intramuscular injection, 4 doses
Study: NCT00208338

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RESTORE SIS Patch
Description: Surgical repair of torn rotator cuff with RESTORE Porcine Small Intestine Submucosa patch (RESTORE SIS Patch) reinforcement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rotator cuff repair
Description: Standard surgical repair of torn rotator cuff
Study: NCT01821755

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Foster parent intervention
Description: parent management training for foster parents, consisting of 10 individual home visits and 3 group sessions. Duration is four months
Study: NCT03370315

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dance Program
Description: The dance program consists of dance classes inspired by the rhythm of Forró and Samba. The sessions are divided into four stages: 1) stretching and sensitization of the body, with the support of chairs; 2) balance and rhythm exercises, with the support of the bar; 3) dance inspired by the genres worked - Forró and Samba; 4) Fun activities that stimulate socialization or with visual clues, working displacements, motor coordination, rhythm, improvisation and creativity. 24 sessions, twice a week, which session take 60 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking Program
Description: The walking program consists of 3 moments: 1) a brief warm-up of free walking for 3 minutes in the comfortable velocity; 2) then walking according to the training cycle, the intensity will be between 60 and 80% of the reserve heart rate; 3) a relaxation. 24 sessions, twice a week, which session take 60 min.
Study: NCT02449187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JLP-1310, Fasted followed by fed
Description: In period 1, the subjects will receive an oral pill of JLP-1310 under fasted condition.~In period 2, the subjects will receive an oral pill of JLP-1310 under fed condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JLP-1310, Fed followed by fasted
Description: In period 1, the subjects will receive an oral pill of JLP-1310 under fed condition.~In period 2, the subjects will receive an oral pill of JLP-1310 under fasted condition.
Study: NCT04079712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO
Study: NCT01030536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-8015 30 mcg/kg
Description: Participants will receive 30 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-8015 40 mcg/kg
Description: Participants will receive 40 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
Study: NCT04079712

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT05231018

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: 8-sessions psychotherapy
Study: NCT00218036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil 200mg
Description: 10 day medication run-up to Modafinil 200mg while subject is methadone maintained at 1/2 mg/kg. On full dose for 12 weeks and then titrated down for 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil 400mg
Description: 10 day medication run-up to 400mg of Modafinil while subject is methadone maintained at 1.2 mg/kg. On full dose for 12 weeks and then titrated down for 10 days.
Study: NCT01563341

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: Study will be utilizing multiple brain electrodes simultaneously. The study will require at least two electrodes to be placed in one cerebral hemisphere (one for motor improvement and one for potential cognitive implications).
Study: NCT03370276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab intravenously (IV) at 240 mg as outlined in the treatment arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab intravenously (IV) at 240 mg as outlined in the treatment arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab intravenously (IV) at 240 mg as outlined in the treatment arms.
Study: NCT01030536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-8015 50 mcg/kg
Description: Participants will receive 50 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-8015 60 mcg/kg
Description: Participants will receive 60 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
Study: NCT03370276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab intravenously (IV) at 240 mg as outlined in the treatment arms.
Study: NCT00218036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram 20mg
Description: 10 day run-up to Citalopram 20mg while subject is methadone maintained at 1.2mg/kg. On full dose for 12 weeks and then titrated down for 10 days.
Study: NCT03370276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab intravenously (IV) at 500 mg/m\^2 or 250 mg/m\^2 as outlined in the treatment arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab intravenously (IV) at 500 mg/m\^2 or 250 mg/m\^2 as outlined in the treatment arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab intravenously (IV) at 500 mg/m\^2 or 250 mg/m\^2 as outlined in the treatment arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab intravenously (IV) at 500 mg/m\^2 or 250 mg/m\^2 as outlined in the treatment arms.
Study: NCT02153957

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: 12 weeks of enhanced physical activity with Zamzee monitor.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity
Description: 12 weeks of enhanced physical activity with Zamzee monitor.
Study: NCT03968822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 2%
Description: 3 mL of test solution to a skin area on the thigh, 2cm in diameter

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine 2%
Description: 3 mL of test solution to a skin area on the thigh, 2cm in diameter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 1%
Description: 3 mL of test solution to a skin area on the thigh, 2cm in diameter

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine 1%
Description: 3 mL of test solution to a skin area on the thigh, 2cm in diameter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%
Description: 3 mL of test solution to a skin area on the thigh, 2cm in diameter

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine 0.25%
Description: 3 mL of test solution to a skin area on the thigh, 2cm in diameter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5%
Description: 3 mL of test solution to a skin area on the thigh, 2cm in diameter

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine 0.5%
Description: 3 mL of test solution to a skin area on the thigh, 2cm in diameter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralipid, 20% Intravenous
Description: a 250ml bag administered intravenously

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline intravenously
Description: a 250ml bag administered intravenously

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: 3 mL of test solution to a skin area on the thigh, 2cm in diameter

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 3 mL of test solution to a skin area on the thigh, 2cm in diameter
Study: NCT01841736

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT01235949

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK1024850A (SynflorixTM)
Description: Intramuscular injection, 4 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK1024850A (SynflorixTM)
Description: Intramuscular injection, 4 doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK1024850A (SynflorixTM)
Description: Intramuscular injection, 4 doses
Study: NCT01841736

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study: NCT01235949

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK1024850A (SynflorixTM)
Description: Intramuscular injection, 4 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK1024850A (SynflorixTM)
Description: Intramuscular injection, 4 doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK1024850A (SynflorixTM)
Description: Intramuscular injection, 4 doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK1024850A (SynflorixTM)
Description: Intramuscular injection, 4 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK1024850A (SynflorixTM)
Description: Intramuscular injection, 4 doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix hexa
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa
Description: Intramuscular injection, 3 doses
Study: NCT00218036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram 40mg
Description: 10 day medication run-up to Citalopram 40 mg while subjects are methadone maintained (1.2 mg/kg). On full dose for 12 weeks and then titrated down for 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo while patient is methadone maintained on standard dose of 1.2 mg/kg
Study: NCT02844023

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Clinical evaluation
Description: With questionnaire.

Intervention type: OTHER
Group type: OTHER
Intervention: Paraclinical evaluation
Description: Symptom inflammatory, biomarkers.

Intervention type: DEVICE
Group type: OTHER
Intervention: Imaging
Description: Thoraco-abdominal scanner injected or PET scanner if contraindication for scanner.

Intervention type: OTHER
Group type: OTHER
Intervention: Ophthalmologic examination

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Dosage of biomarkers
Description: Control patients.
Study: NCT03273738

Intervention type: DIAGNOSTIC_TEST
Intervention: folate level measurement
Description: the level of folate measured in plasma with homocysteine

Intervention type: DIAGNOSTIC_TEST
Intervention: folate level measurement
Description: the level of folate measured in plasma with homocysteine

Intervention type: DIAGNOSTIC_TEST
Intervention: B12
Description: B12 measurement in blood

Intervention type: DIAGNOSTIC_TEST
Intervention: B12
Description: B12 measurement in blood
Study: NCT01966562

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WHOLE-BODY VIBRATION TRAINING
Description: The vibration stimulus consisted of uniform vertical oscillations Power Plate® Next Generation (Power Plate North America, Northbrook, IL, USA). Subjects stood on the platform holding an quarter squat positions with the feet shoulder-width apart. Then, they perform ankle extensions with the following work sequence (establishing a rhythm of 100 b.p.m.: 1 b.p.m for the concentric phase; and 5 b.p.m. for the eccentric phase). After the familiarization 2-weeks, subjects trained 3 days per week for 6-months (72 sessions) using a vibrating training program that began with 5 sets and a frequency of 35 Hz per session and increasing by 11 sets and 40 Hz frequency the last month maintaining a series of parameters: vibration amplitude (4 mm) working time (60 s) and recovery time (60 s).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MULTICOMPONENT TRAINING
Description: This training combined vertical jumps and high intensity walking. During the first month, small reactive vertical jumps (without knee and ankle flexion) were performed. After the first month, subjects performed drop jumps progressively starting at a height of 5 cm and finishing at 25 cm at the end of the programme (increases of 5 cm each month). Additionally, the sets were increased from 4x10 jumps to 6x10 each week, finishing the last week with 4x10. In this sense, the drop jumps were the same each month but the total load (imposed by height) increased progressively. Regarding the aerobic exercise, the load increased progressively along the 6 months. The intensity ranged between 50-75% of reserve heart rate, the volume ranged between 30-60 min.
Study: NCT01841736

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO
Study: NCT01452958

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNF-alpha
Description: Study protocol 1: 6 ng/kg/h intraarterial Study protocol 2: 18 ng/kg/h intravenous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endotoxin
Description: Study protocol 2:0,075 ng/kg/h intravenous
Study: NCT02929563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Study: NCT01841736

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT02929563

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for pantoprazole)
Study: NCT01841736

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo chest x-ray

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: X-Ray Imaging
Description: Undergo chest x-ray
Study: NCT04352322

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: A+HA(tm)
Description: oral solution of hyaluronic acid mixture in combination with glucosamine and chondroitin

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral solution with no active ingredients
Study: NCT01014637

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amorolfine (Antifungal)
Description: Treatment with Amorolfine for 36 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV4104A, Ciclopiroxolamine, Cyclopirox (Keratolytic Agents/Antifungal)
Description: Initial treatment with RV4104A ointment for 3 weeks, followed by treatment with ciclopiroxolamine 1% cream for 8 weeks and by cyclopirox 8% film-forming solution for 25 weeks.
Study: NCT01957826

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bone marrow-derived MSCs injection
Description: transendocardial injection of 30-40 million bone marrow-derived MSCs with the NOGA XPTM platform. 15 injections in the anterior wall of the left ventricle.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo intervention
Description: placebo administration